3-phosphoinositide-dependent protein kinase 1 104
5-fluorouracil 475, 1254, 1483
8-oxodG 1018
α-tocopheryl succinate 1224
α-trinositol 833
ABCG2 1276
acoustic neuroma 1654
acquired resistance 383
actomyosin contractility 392
ADCC 520
adenocarcinoma 1692
adenoma 765
adenovirus 796
adipocytes 403
adipose tissue 1541
AdnaTest 276
advanced breast cancer 1341
advanced disease 1687
advanced gastric cancer 475
advanced oesophageal cancer 475
adverse events 80
AEE788 1235
AFP 748
Africa 957
African breast cancer 369
aftercare 1447
Akt 1163
AKT1 1491
alanine aminotransferase 1371
albumin 1113
ALDH1 369
alternative fusion gene 436
Amsterdam II criteria 482
anaemia 301
anaesthesia 1555
anal cancer 1123
angiogenesis 8, 196, 530, 837, 1524, 1592, 1636
angiogenesis inhibitors 268
animal welfare 1555
anoxia 561
anti-angiogenic 495, 594
antibody 500, 827
anti-EGFR therapy 151
anti-neoplastic 1361
anti-TPO antibodies 852
anti-tumour activity 1099
APE1 704, 1600
apoptosis 97, 104, 165, 383, 506, 577, 583, 873, 1010, 1474, 1592, 1707, 1717
arachidonic acid 403
aromatase 1235
AS1402 827
ascorbic acid 1224
Asian continental ancestry group 1438
aspirin 1415
assessment of treatment response 35
attributable fraction 1428
autotaxin 941
β43–63 594
β-catenin mutation 1032
Barrett's oesophagus 1608
basal-like 369
BC 815
Bcr-Abl 1474
betaine 489
bevacizumab 80, 268, 495, 981, 1468
biliary tract cancer 68, 1185
bilirubin 1371
bioinformatics 1244
biomarkers 8, 268, 361, 462, 1174, 1378, 1524
birth order 1670
birth weight 227
bispecific antibody 124
bisphosphonates 799
BiTE 124
Blacks 1676
bladder cancer 883
BMI-1 369, 892
body mass index 610, 966
bone diseases 651
bone loss 645
bone marrow 403
bone metastasis 332, 457
bone mineral density (BMD) 294, 645
BRAF 151, 1724
BRAF mutations 1762
BRAF oncogene 482
brain 1219
brain metastasis 1213
brain tumour 1786
BRCA1 1061, 1091
BRCA2 1091
BRD8 325
breast cancer 35, 42, 213, 220, 276, 342, 351, 361, 462, 489, 645, 799, 827, 941, 1003, 1010, 1024, 1081, 1099, 1235, 1284, 1294, 1461, 1495, 1503, 1645, 1665, 1736
breast cancer risk 1400
breast imaging 35
breast neoplasms 651, 1391
breast screening 285
brucein D 583
C1QA 1294
C20orf20 (MRGBP) 325
CA4P 1355
cachexia 665, 833
cancer burden 1428
cancer incidence 620
cancer incidence trends 1411
cancer screening 1085
cancer stem cell 789
cancer survivors 1085
capecitabine 59, 475, 981, 987, 995, 1468, 1687
carbonic anhydrase IX 1627
carboplatin 1355
carcinoembryonic antigen 124
carcinogenesis 1391, 1428
carcinoma 1533
case–control 615, 799
CCBE1 87
CCSQ-FACIT 59
CD133 1265
CD24 206
CD-31 530
CD44 206
Cdc25A 1361
CDK 342
CECs 268
cell cycle 873
cell flow experiments 602
cell lines 553, 898, 1618, 1769
cell migration 1145
cell proliferation 325
cell-cycle arrest 1578
CellSearch System 276
cellular adhesion 1541
cellular FLICE inhibitory protein (c-FLIP) 754
cervical cancer 23, 196, 933, 1657
cervical screening 933, 1405
cetuximab 162, 500, 520, 1137
chemoradiation 1123
chemoresistance 1717
chemosensitivity 541
chemotherapy 115, 294, 500, 629, 810, 1099, 1106, 1313
childcare 1670
childhood cancer 620, 1670
childhood leukaemia 796
Child–Pugh 748
chimeric protein 436
Chinese 610
CHK1 862
chloride channel 4 774
Choi criteria 803
choline 489
chromosomal translocation 436
chromosome 243
chromosome aberration 1044
CIN 933, 957
circulating biomarker 577
circulating tumour cells 276, 561, 1327, 1495
cisplatin 383, 475
class III β-tubulin 316
clonogenicity 1145
CML 1474
c-myc 892
CNS disease 995
CNS lymphoma 673
CNS tumour 1670
cohort 489
colon cancer 165, 754, 1145, 1265, 1753
colony survival 1578
colorectal adenocarcinoma 1384
colorectal cancer 48, 59, 151, 162, 325, 447, 506, 765, 774, 908, 916, 972, 1254, 1327, 1519, 1746
colorectal liver metastases 1313
colorectal neoplasms 1468
colorectal tumour 693
combretastatin A4 phosphate 1355
conjunctiva 262
contralateral breast 213
copy number 1378
cost 80
COX-2 916
CRC 1137, 1300
C-reactive protein 1113
CSC 1265
cumulative risk 42
cutaneous melanoma 1213, 1447
cyclin D1 1378
cyclin D1 expression 1762
cyclooxygenase-2 765
cyclophosphamide 1003
cyclophosphamide, vincristine, and prednisone 19
CYP2D6 294
cytarabine 673
cytokeratin 18 577
cytology 933, 1180, 1405
cytolytic killing 124
cytomegalovirus 1665
cytotoxicity 852
DASL 570
DBC1 1061
DCIS measurement 285
DDC 1384
death receptor 5 (DR5) 754
dendritic cells 115
DHMEQ 206
diagnostic accuracy 48, 181
diagnostic imaging 651
dichloroacetate 1746
differential allelic expression 1294
digalloyl-resveratrol 1361
discrete choice experiment 972
disease-free survival 719
distant relapse 428
DNA arrays 462
DNA damage 862, 1578
DNA methylation 419
DNA ploidy 1608
DNA repair 1018
docetaxel 475
doxorubicin 361, 1003
drug resistance 1265, 1276, 1636
drug target 1265
drug-interaction 1699
dynamic contrast-enhanced MRI 23
E17K 1491
E2F1 protein 1753
E6/E7 mRNA 957
early detection 1681
early growth response gene-1 (Egr-1) 754
early-stage cervical cancer 1692
EG3287 541
EGF 457
EGFR 144, 165, 500
EGFR pathway 1778
ELISA 1524
EMT 639
encapsulated follicular thyroid tumour 376
endometrial cancer 134, 952, 1201
endothelial 594
enhanced retroviral mutagenesis 774
enhancing fraction 23
epithelial tumours 436
epithelial-to-mesenchymal transition (EMT) 351, 844, 898
Epstein–Barr virus 1665
ERBB 457
ErbB2/Her2 513
ERCC1 1600
ERG/ETV1 gene rearrangements 678
erlotinib 268
erythropoiesis-stimulating agent 301
E-selectin 602
ethnicity 249
EWS-Oct-4B 436
exfoliated cell 916
exome 243
expression profile 1769
extracellular matrix 1541
faeces 916
familial breast cancer 42, 1091
familial risk 1786
family history 237, 1091, 1676
fatty acids 1736
FDG-PET 35
FGFR3 1145
fibrinogen 594, 952
fibroblast 1533
fibroblast growth factor receptor 188
fibromatosis 1032
FISH 1495
fluorescence in situ hybridisation 678
Folate receptor α 553
follicular adenoma 376
follicular lymphoma 19
follicular thyroid carcinoma 376
follow-up 1447
formylpeptide receptor 1052
fracture risk 645
FSCN1 883
fundamental and translational research 1555
γH2AX 1511
G protein-coupled receptor 941
gabarapl1 1024
gallstones 1185
gastric cancer 237, 500, 665, 710, 738, 1174
gastro-oesophageal cancers 704, 1600
Gb3 383
gene amplification 693
gene expression 361, 414, 428, 1284, 1636
gene expression profiling 206
genetic instability 1300
genetically engineered mouse models 1555
genome 243
genotyping 930
gestational age 227
glioblastoma 1052
GPRD 1415
grandmaternal age 1400
GSTP1 987
GTN 810
guidelines 645
haemostasis 594
HCC 748, 1618
hCG 810
head and neck cancer 181, 1687
health transition 1438
health-related quality of life 19, 658
hedgehog signalling pathway 738
hepatocellular carcinoma 981, 1483
HER2 815, 1495
Her2+ metastatic breast cancer 995
HER2 signalling 1503
HIF 789
high-dose chemotherapy 673
high-grade dysplasia 1608
histologically normal epithelium 1284
histone γH2AX 1578
HLA1 115
HNPCC 1068
HNSCC 1778
Hospital Discharge Registry 1397
housekeeping genes 1037
HPCs 268
HPV 930, 1657
HPV DNA 957
HPV testing 1405
HPV vaccination 933
HuHMFG1 827
human papillomaviruses 262, 1044
human tumour xenografts 1555
humane endpoints 1555
hyperthyroidism 1397
hypoxia 351, 428, 561, 789
hypoxia inducible factor (HIF) 351
hypoxia resistant 898
Id-1 332
IE63 727
IFN-α 873
IFN-γ-producing cells 748
ifosfamide 1699
IL-21 520
image cytometry 1608
imaging 1555
imaging biomarkers 23
imaging techniques 1555
imatinib 1219
imiquimod 1129
immunohistochemistry 144, 181, 553, 704, 892, 1018, 1157
immunoinflammation 73
ImmunoRNase 513
immunotherapy 115, 513, 852
immunovisibility 115
in silico 414
industry sector 1428
infectious disease 1670
inflammation 941, 1113, 1180
informing patients 1081
inositol polyphosphates 104
insulin-like growth factor-binding protein 7 (IGFBP7) 1483
integrin 541
interaction 1061
interferon 1456
interferon-α 1483
intergenic and intronic DMR 419
International Neuroblastoma Risk Group (INRG) 1319
Internet support 1348
intraductal 1391
intravital microscopy 837
invasion 196, 392, 774, 1052
ionising radiation 1511
irinotecan 987
IVIS 1618
joinpoint analysis 1411
kallikrein 1244
Ki-67 1106, 1391, 1645
Ki-67 antigen 1753
kidney cancer 1676
KIT 1219
KLK 1244
KRAS 151, 693, 1254
KRAS mutation 500
lapatinib 995
LASP-1 1645
L-DOPA decarboxylase 1384
letrozole 1010, 1235
leukaemia 620
linear two-compartment 827
lipid 403
liver metastases 255
liver resection 255
LMWH 837
locoregional control 1778
long-term follow-up 1123, 1405
luminal 815, 1736
lung cancer 27, 610, 1180, 1190, 1495, 1533, 1681, 1731
lymph node positive 1024
lymphendothelial retraction 1361
lymphoma 620
Lynch syndrome 482
lysophosphatidic acid 941
M30 577
M65 577
macrophage inhibitory cytokine 1 665
magnetic resonance spectroscopy 1
malignancy 727
malignant melanoma 1157
malnutrition 966
mammographic screening 1461
management 80
mapatumumab 506
mass screening 27, 469
mass spectrometry 1265
maternal age 1400
matrix remodelling 392
MCF-7 cells 316
MDA-MB-231 cells 316
MDR1/P-gp 1157
MeDIP-chip 419
megestrol acetate 1207
melanoma 1219, 1707, 1724
MEPE/OF45 862
mesothelioma 383, 553
meta-analysis 301, 428
metabolism 1
metalloproteinase 457
metastasis 403, 561, 602, 867, 1618
metastatic colorectal cancer 987, 1762
metastatic models 1555
metastatic renal cell carcinoma 658
metastectomy 255
method validation 1524
methotrexate 673
metronomic cyclophosphamide 1207
mIBG 1319
microarray 570, 1541
microenvironment 774, 1533
microRNA 883, 1174, 1769
microsatellite instability 482
microtubule disruptor 316
migrants: England and Wales 1438
migration 541, 710, 774
minimal disease 1319
minimally invasive surgery 1313
miR-133a 883
miR-145 883
miRNA 376, 1244
mismatch repair 144, 1068
mitochondria 1717
mitotic index 1106
MKP-1 1137
MMP 922
MMP-9 530
MMR gene promoter methylation 482
modelling 933, 1201
molecular marker 1137
mortality 867, 1438
MRP-1 1157
MSH3 1068
MSI status 1762
MSMB 414
multimodal 73
multiple drug resistance 1157
mutation 693, 1219, 1491
MutSα 1068
MutSβ 1068
MyD88 908
myoglobin 1736
nadroparin 837
natural history 213
NB 685
necrosis 577
neoadjuvant 1099
neoadjuvant chemotherapy 1600
neoplasm metastasis 1468
NETs 1106
neuroblastoma 615, 1319
neurosurgery 1213
NF-κB 206, 639, 1163
non-coding RNA 419
non-invasive biomarkers 1
non-small cell lung cancer 97, 1113, 1627
normalisation 1037
Notch 351
Notch1 196
Noxa 1254
NS398 765
NSAIDs 1415
NU2058 342
NU6102 342
NUB1 873
nutrition 665
obesity 966
occupation 1428
oesophageal adenocarcinoma 1608
oesophageal cancer 73, 665, 1378
oestrogen receptor 294, 1736
oestrogen receptor-α 738
Okuda 748
older age 1461, 1468
oocyte 1400
oral cancer 892
orthotopic models 1555
osteoblast 332, 457
osteoclast 332, 457
osteonectin 188
osteoporosis 799
outcome 1163
ovarian cancer 87, 495, 704, 1244
ovarian cancer stem-like cells 1276
overall survival 719, 1769
oxaliplatin 987, 1254
oxidative stress 1018
p27 1235
p53 719, 1254, 1600, 1645
paclitaxel 316, 1355
paediatric 620
paediatric rhabdomyosarcoma 227
Pakistan 1657
palliative chemotherapy 1207
PANC-1 cells 583
pancreatic adenocarcinoma 704
pancreatic cancer 188, 577, 583, 1415, 1422
pancreatic stellate cells 188
papillary thyroid carcinoma 376
paternal occupation 615
pathological response 1099
patient age 947
patient-reported outcomes 658
pazopanib 1371
PBOX 1474
PCR 1037
PDEF 1645
pemetrexed 553
Pemphigus vulgaris antigen 181
peri-operative chemotherapy 255
peripheral nerve tumour 1786
personalised medicine 693
pertuzumab 134
pharmacogenetics 1003, 1371
pharmocokinetic, pharmacodynamic and efficacy studies 1555
pharmacokinetics 673, 1699
phase I trial 1355, 1699
phase II trial 68, 506
Philippines 1411
phosphoinositide 3-kinase 104
phosphorylated EGFR 165
phosphorylation inhibitor 844
photodynamic therapy 1608
PI3K 1163, 1491
PI3K/Akt 196
pilot studies 1555
pituitary tumour 1654
plasma 1174, 1378, 1627
platelets 1524
platinum pretreated 1687
pleural effusion 1180
pleural fluid 1180
point counting 1519
polymorphism 237, 294, 447
population pharmacokinetic 827
portal vein embolisation 1313
postmenopausal 1201
postoperative 1327
PPARγ 685
predictive 867, 1201
pregnane X receptor 1753
pre-invasive 1391
prenatal infection 796
PreTect HPV-Proofer 957
prevalence 1657
preventative care 1085
primary breast cancer 719
primary care 48, 1085
primary care delay 947, 1447
primary systemic therapy 35
pro-coagulant 73
prognosis 165, 731, 892, 908, 922, 952, 1024, 1113, 1327, 1627, 1692
prognostic 173, 1032
proliferation 165, 710, 738
prophylactic mastectomy 1284
proportion of tumour 1519
prospective cohort 610
prostate biopsy 1335
prostate cancer 249, 332, 403, 414, 570, 678, 922, 1163, 1224, 1491
prostatic neoplasms 469
protein kinase B-Akt 104
proteinchip 1731
proteomics 1731
PSA 469, 922, 1335
P-selectin 602
PSMB7 361
psychological distress 1335
psychological measures 1348
PTEN 162, 1163, 1778
PTEN gene loss 678
PVTT 1618
pyruvate dehydrogenase 1746
QLQ-C30 59
quality of life 27, 59, 1341, 1456
quality-adjusted survival 19
quantification 1037
Rab 392
race 1676
radiation 220
radical hysterectomy 1692
radiology 285
radiosensitivity 1511, 1778
radiotherapy 23, 220, 1555
randomised controlled trials 469, 1081, 1207, 1348
RAS 1137
RCC 873
reactive oxygen species 583, 1018
real-time PCR 1384
receptor tyrosine kinase inhibitor 658
RECIST 803
rectal bleeding 48
recurrence 570, 1327
rehabilitation 1348
relapsed SCLC 629
REMARK 173
renal cell cancer 803, 867, 1371, 1456, 1592, 1676
replacement, reduction and refinement (3Rs) 1555
reporting guideline 173
repression 1061
reproductive factors 1185
resistance 513, 1724
response assessment 651
response criteria 1319
restraint 1555
Revised Bethesda Guidelines 482
RGZ 685
rhabdomyosarcoma 1769
RhoC 196
ribonucleotide reductase 1361
risk 220, 1201, 1284, 1294
risk factors 645, 966
rituximab 19
RLB 957
RNA 916, 1037
RNA interference 361
RT–PCR 276
sarcoma 1207
sarcoma patients 731
scirrhous gastric cancer 844, 898
Scotland 930
screening 462, 972, 1335, 1681
screening recommendations 42
seasonal variation 1670
second primary neoplasms 220
secondary care referral 947
SELDI-TOF-MS 1731
sensitivity and specificity 469
sentinel lymph nodes 181
sequencing 243
serum amyloid A 1731
serum biomarker 1731
serum lactate dehydrogenase 1213
sex differences 1190
side population 1276
Singapore 610
skin cancer 1661
skinfold chamber 837
SMAC-mimetics 1707
Smad2 844
small bowel adenocarcinoma 144
small cell lung cancer 629
smoking 610, 1654
Snail 639, 892
SNP 414, 1294
SNP array 1044
socioeconomic status 719, 1661
sodium 867
Sonic hedgehog 738
sorafenib 68, 268, 495, 1219
SP 815
SPARC 188, 530
SPCs 1190
spinal tumour 1786
spiral computed tomography 27
spiral CT 1681
squamous cell carcinoma 262, 1692
stability 1524
Stage IV colorectal cancer 255
stage of disease 748
STAT3 1592
stathmin1 710
statistical model 1503
stem cells 369
stereotactic radiosurgery 1213
stromal cells 1533
stromal fibroblast 392
STX140 316
subsequent cancer 1397
sunitinib 80, 658, 803, 1699
surgery 1313
survival 665, 678, 1213
survival analysis 173, 1113
survivorship 1348, 1447
synergy 1010, 1224
T regulatory cells 1129
T315I 1474
tamoxifen 294, 1235
tamoxifen resistance 1503
targeted therapeutics 1
T-cell responses 727
telomere 1300
temsirolimus 1456
TGCT 419
TGF-β 844
therapeutic HPV vaccination 1129
therapeutic target 1145
therapy 1555, 1724
thyroid cancer 852
TIC 1618
T-ICs 815
TIMP 922
tissue microarray 922, 1627
TLR4 908
TMPRSS2–ERG fusion 570
TNF-α 639
TOPK 151
TP53 1091
TRAIL 1707
TRAIL-R1 506
transcriptome 243
transformation 436
trastuzumab 134, 513, 520
treatment 629
treatment benefits 1341
treatment toxicity 1341
trends 620, 1661
tumour attenuation 803
tumour biomarkers 1384
tumour burden 1555
tumour cell glycoconjugates 602
tumour growth 833
tumour markers 173, 1180, 1244
tumour models 1555
tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) 754
tumour progression 1391
tumour regression grade 1600
tumour response 803
tumour suppressor 87
tumourigenesis 1276
tumour-initiating cells 206
type I extrinsic apoptotic pathway 754
UGT1A1 1371
urokinase plasminogen activator system 731
uterine serous papillary cancer 134
varicella zoster virus 727
vascular disrupting agent 1355
vascular endothelial growth factor 144
VEGF 8, 530, 541, 1699
verotoxin-1 383
VIN 1044
virtual slides 1519
vitamin D 1422
vitamin E 1224
vitamin K3 1224
VSCC 1044
vulva 1044
vulval intraepithelial neoplasia (VIN) 1129
wasting 1541
weight loss 966
whole-genomic microarray 765
women 489, 1654
XAC 1396-11 97
xenograft 561, 602, 685, 1636
XIAP 97, 1717
zinc 833
ZOL 1099
zoledronic acid 1010
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Keyword Index for Volume 102. Br J Cancer 102, 1802–1805 (2010). https://doi.org/10.1038/sj.bjc.6605729
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6605729